Showing 6231-6240 of 10148 results for "".
- Participating in an AD Trial: Weighing What Matters Most to Patients and Parentshttps://practicaldermatology.com/news/participating-in-an-ad-trial-weighing-what-matters-most-to-patients-and-parents/2461714/Key differences exist between what adults with eczema value for themselves in clinical trial participation versus what parents find important for their kids with this chronic skin disease, according to new research from the
- Arctiva Eczema Cream Spells Relief for 91% of Patientshttps://practicaldermatology.com/news/study-arctiva-eczema-cream-spells-relief-for-91-of-patients/2461688/Fully 91% of participants reported improvement in eczema irritation using proprietary Arctiva Eczema Cream, a new study shows. Arctiva Eczema Cream features Hydrosurf glycolipid technology—a blend of fermented ingredients with origins from Antarctica. It is combined with 1% C
- The Melanoma Research Alliance, SPOTMYUV Continue Partnership to Promote Sun Safetyhttps://practicaldermatology.com/news/the-melanoma-research-alliance-spotmyuv-continue-partnership-to-promote-sun-safety/2461685/The Melanoma Research Alliance and SPOTMYUV are renewing their partnership to promote sun safety and effective use of sunscreen. The two organizations will co-develop sun safety and skin cancer prevention materials that empower consumers to protect themselves and those they love from UV
- Meet Zerigo 2.0: Upgraded System Allows Patients to Better Manage Psoriasis and Eczema at Homehttps://practicaldermatology.com/news/meet-zerigo-20-upgraded-system-allows-patients-to-better-manage-psoriasis-and-eczema-at-home-2/2461681/Zerigo Health is rolling out the Zerigo 2.0 ecosystem, the newest iteration of its digital health platform for the treatment and management of chronic skin conditions like eczema and psoriasis to employers, health plans, and their provide
- Incyte Scores Vitiligo Nod for Opzelura Cream in Europehttps://practicaldermatology.com/news/incyte-scores-nod-for-opzelura-cream-for-vitiligo-in-europe/2461674/The European Commission (EC) has granted a marketing authorization for Opzelura (ruxolitinib) cream15mg/g for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. The selective JAK1/JAK2 inhibi
- Galderma Survey Debunks Filler Mythshttps://practicaldermatology.com/news/galderma-survey-debunks-filler-myths/2461668/Forty percent of people say they would discourage others from using facial injectables to reduce wrinkles or provide volume, and 34% said they believed the results of such treatments look fake and unnatural, according to a new poll sponsored by Galderma. Despite these views, the same re
- Smart Wound Dressing Can Spot Infection Earlyhttps://practicaldermatology.com/news/smart-wound-dressing-can-spot-infection-early/2461666/A nanocellulose wound dressing that can reveal early signs of infection without interfering with the healing process has been developed by researchers at Linköping University, Sweden. The study is published in Materials Today Bio. Researchers at Link&o
- USPSTF Final Recommendation: There’s Not Enough Evidence to Support Skin Cancer Screening in Folks Without Symptomshttps://practicaldermatology.com/news/uspstf-final-recommendation-theres-not-enough-evidence-to-support-skin-cancer-screening-in-folks-without-symptoms/2461665/
- AARS Shines Light on Antibiotic Resistance During Rosacea Awareness Monthhttps://practicaldermatology.com/news/aars-shines-light-on-antibiotic-resistance-during-rosacea-awareness-month/2461664/The American Acne and Rosacea Society (AARS) is calling on patients and prescribers to ensure appropriate use of antibiotics to manage rosacea during Rosacea Awareness Month. “It has been well known for many years that dermatologists prescribe more antibiotics per clinician than p
- Adding New Personalized Vaccine to Immunotherapy Slashes Risk for Melanoma Recurrencehttps://practicaldermatology.com/news/adding-new-personalized-vaccine-to-immunotherapy-slashes-risk-for-melanoma-recurrence/2461662/Adding an experimental mRNA vaccine to immunotherapy reduced the likelihood of melanoma recurring or causing death by 44% when compared with immunotherapy alone, a new clinical trial shows. The phase 2b trial results were presented at the annual meeting of the American A